These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33901557)
1. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL Wang R; Hu Q; Wang H; Zhu G; Wang M; Zhang Q; Zhao Y; Li C; Zhang Y; Ge G; Chen H; Chen L Int J Biol Macromol; 2021 Jul; 183():182-192. PubMed ID: 33901557 [TBL] [Abstract][Full Text] [Related]
2. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603 [TBL] [Abstract][Full Text] [Related]
3. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Hajbabaie R; Harper MT; Rahman T Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721 [TBL] [Abstract][Full Text] [Related]
4. Prioritisation of Compounds for 3CL Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U Molecules; 2021 May; 26(10):. PubMed ID: 34070140 [TBL] [Abstract][Full Text] [Related]
5. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related]
6. Exploring 2-methyl-substituted vitamin K Koharazawa R; Hayakawa M; Takeda K; Miyazaki K; Tode C; Hirota Y; Suhara Y Bioorg Med Chem Lett; 2024 Mar; 100():129642. PubMed ID: 38310976 [TBL] [Abstract][Full Text] [Related]
7. Discovery of highly potent covalent SARS-CoV-2 3CL Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network. Gu Z; Yan Y; Liu H; Wu D; Yao H; Lin K; Li X J Chem Inf Model; 2024 Apr; 64(8):3047-3058. PubMed ID: 38520328 [TBL] [Abstract][Full Text] [Related]
9. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428 [TBL] [Abstract][Full Text] [Related]
10. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006 [TBL] [Abstract][Full Text] [Related]
11. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292 [TBL] [Abstract][Full Text] [Related]
13. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library. Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246 [TBL] [Abstract][Full Text] [Related]
14. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL Jukič M; Janežič D; Bren U Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996 [TBL] [Abstract][Full Text] [Related]
15. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954 [TBL] [Abstract][Full Text] [Related]
17. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279 [TBL] [Abstract][Full Text] [Related]
18. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027 [TBL] [Abstract][Full Text] [Related]
19. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923 [TBL] [Abstract][Full Text] [Related]
20. A Patent Review on SARS Coronavirus Main Protease (3CL Chia CSB; Xu W; Shuyi Ng P ChemMedChem; 2022 Jan; 17(1):e202100576. PubMed ID: 34651447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]